GT 863
Alternative Names: GT863Latest Information Update: 28 May 2019
At a glance
- Originator Pharmaspur Inc
- Class Antidementias
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 28 May 2019 No recent reports of development identified for phase-I development in Alzheimer's-disease(In volunteers) in Japan
- 15 Jun 2016 Pharmaspur completes a phase I trial in Alzheimer's disease in Japan (UMIN000021672)
- 05 Apr 2016 Phase I trials in Alzheimer's disease (In volunteers) in Japan (unspecified route) (UMIN000021672)